Who was studied, and how
Two numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 23 other studies
252people in the A Randomized, Double Blind, Parallel, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A in Patient With Primary Hypercholesterolemia or Mixed Dyslipidemia trial, from 2022
of them with dyslipidemia, aged 19+, in this paper
The trial randomly assignedassigned by chance
low-intensity atorvastatin (5 mg) plus ezetimibe (10 mg) combination therapy (A5E10)
atorvastatin 5 mg [A5]
Reported lower LDL-C reduction, no range given−47.6
randomisedthe abstract, start to end
… significantly greater LDL-C reduction (47.6%) compared with A5 (33.4%), E10 …
… was observed over the 4 weeks, with a 46.7% reduction in LDL-C levels …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
LDL-C reductionlow-intensity atorvastatin (5 mg) plus ezetimibe (10 mg) combination therapy (A5E10) vs atorvastatin 5 mg [A5]
−47.6
LDL-C levelslow-intensity atorvastatin (5 mg) plus ezetimibe (10 mg) combination therapy (A5E10)
−46.7
StatinsOther lipid agentsLipids
Other lipid agents × lipidshelps?mixed
unlikelylikely
0.500.50 without it
Statins × lipidshelps?mixed
unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
1 / 7